No Prescription |
 |
 | ||
|
Aprovel Avapro |
|
| ||
No Prescription » Prescription Drugs 2 » Aprovel Avapro This drug is used to treat high blood pressure (hypertension) and to help protect the kidneys from damage due to diabetes. High blood pressure reduction helps prevent strokes heart attacks and kidney problems. This drug works by blocking the hormone angiotensin thereby relaxing blood vessels causing them to widen. Irbesartan belongs to a class of drugs called angiotensin receptor blockers. Buy Aprovel Avapro and other Prescription Drugs 2 products online at Medstore. Buy Online at Medstore - Click Here!
About Aprovel Avapro: Product Type: Prescription Drugs 2 Aprovel ( Avapro Generic Irbesartan ) Aprovel (Avapro Generic Irbesartan) Avapro Generic Irbesartan 150mg 14 Tablets 150mg 42 (3 x 14 Tablets) 150mg 84 (6 x 14 Tablets) 300mg 14 Tablets 300mg 42 (3 x 14 Tablets) 300mg 84 (6 x 14 Tablets) Avapro Generic Irbesartan Aprovel
View more Prescription Drugs 2 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
